Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Abstract

The Golgi apparatus-complex (GA), is a key organelle involved in several posttranslational modifications of polypeptides destined for lysosomes, plasma membranes and secretion. As reported from this laboratory, certain astrocytes in rat brain contain cisternae of the GA not only in perikarya, but also in processes. In order to further investigate which type of astrocytes contain GA in processes we conducted the present study using primary cultures of rat astrocytes and organelle specific antibodies against the GA and the rough endoplasmic reticulum (RER). While the perikarya of all cells contained elements of the GA, only a single process of a subset of type I astrocytes, negative to antibodies A2B5 and HNK-1, contained GA. In contrast, elements of the RER were found within perikarya and all processes. In order to confirm that the immunostained structures in processes indeed represent the GA, we exposed cultures to Brefeldin A (BFA), a secretion blocker which disperses the GA and redistributes it to the RER. We observed that BFA disrupted the GA of both perikarya and processes. However, astrocytes were resistant to prolonged incubations with BFA, while a similar treatment killed cultured fibroblasts and PC-12 cells. Furthermore, in astrocytes exposed to BFA for several days, the delicate network of glial fibrillary acidic protein (GFAP), was replaced by large perinuclear masses of the protein. These observations demonstrate that a subset of type I astrocytes have a single process with elements of the GA. We suggest that this specialization of the GA may be related to yet unrecognized secretory or protein processing functions of these cells. The resistance of astrocytes to BFA and the striking changes in their cytoskeleton induced by the drug, may contribute to studies on the mechanism(s) of action of BFA.

Key words: Golgi apparatus; Brefeldin A; Glial fibrillary acidic protein; Astrocyte type I; Astrocyte type II; MG-160; Electron microscopy; Immunohistochemistry; A2B5; HNK-1; Cell process

1. Introduction

The GA plays a pivotal role in secretion, plasma membrane biosynthesis and targeting of lysosomal enzymes [20]. The organelle is involved in numerous posttranslational modifications and in the sorting or targeting of processed polypeptides. In addition to the general properties of the organelle, cell specific features of the GA, such as selective production of certain enzymes (e.g. high PAPS cerebroside sulfotransferase in neuronal GA), have been identified [3,22,36,39,40,49,62]. Astrocytes are actively involved in numerous secretory functions such as production of cytokines and growth factors [24,25,46]. It is therefore reasonable to speculate that the GA of astrocytes would express function-related properties of the GA.

Astrocytes, recognized by their specific cytoskeleton protein GFAP, are not a homogeneous population of cells [45,74]. In tissue sections, astrocytes can be divided by morphological criteria into 'fibrous' (mostly in the white matter) and 'protoplasmic' (mostly in the gray matter). Additional markers such as the monoclonal antibody A2B5 [15] and tetanus toxin are positive in cultures of astrocytes with numerous delicate branching processes (type II) and negative in flat astrocytes (type I) [58]. Additional evidence suggests a dual lineage of the two types of astrocytes in some culture
systems [44,59]. Type I astrocytes and their processes envelop blood vessels, suggesting a function related to the blood brain barrier (BBB); also, type I astrocytes proliferate in response to injury, while type II astrocytes are associated with the nodes of Ranvier and die in response to axonal injury [52]. There is no clear parallel between the in vivo and in vitro classifications of astrocytes. Moreover, there is some question as to whether or not type II astrocytes have an in vivo analogue [53]. Astrocyte heterogeneity has been reported even within a morphologically distinct group, particularly for type I astrocyte cultures [74]. This includes heterogeneity in ion channel, expression of neurotransmitter receptor and glycoprotein, neuropeptide and cytoskeletal content, prostaglandin and peptide secretion, influence on neuronal differentiation, as well as morphology [4,29,45,51,74].

The use of organelle-specific markers is central to this study. Since the conceptualization of the secretory pathway [57], several groups have developed organelle-specific antibodies as a tool to study the GA and other organelles of the secretory-endocytic pathways [7–11,26,48,64,65,75]. In this laboratory an intrinsic membrane sialoglycoprotein (MG-160) of medial cisternae of the GA, was purified from rat brains [26]. The original monoclonal antibody, 10A8, used in the isolation of MG-160 from rat brains, reacts only with rat tissues. However, a polyclonal antiserum raised against immunoaffinity purified MG-160 reacts with several species and cell types, including human [11], suggesting that MG-160 or closely related molecules are conserved polypeptides of the GA.

In a previous ultrastructural, immunocytochemical study from this laboratory, using affinity-purified polyclonal sera specific for the GA, elements of the organelle were detected in peripheral segments of some astrocytic processes in sections of rat brains [68]. Other glial cells did not display extensions of the GA in processes. This localization of the GA in processes of astrocytes, and the investigation of other structural properties of the GA of astrocytes is the subject of the present study. In this study in order to further investigate the properties of elements of a putative GA in astrocytic processes, we used primary cultures of astrocytes and the organelle-specific antisera against the GA and the RER [8,11,26]. The primary culture model offers the opportunity of experimental manipulations and better resolution of immunocytochemical staining, not easily obtainable in in vivo studies. To further ascertain whether immunostained elements indeed represented the GA, we exposed cultures to BFA, a secretion blocker, which disrupts the GA and induces its redistribution into the RER [12,47]. Results of this study indicate that processes of a subpopulation of astrocytes display elements of the GA in a polarized fashion.

2. Materials and methods

2.1. Cell cultures

Primary glial cell cultures were prepared from newborn Lewis rats (Charles River Laboratories) as previously described [41,42,70,71]. The method for the preparation of the glial cultures was adapted from the original method of McCarthy and de Vellis [50]. Careful removal of meninges resulted in minimal contamination of cultures by fibroblasts. Over 95% of the cultured cells stained with the monoclonal antibody against GFAP [43], an astrocyte specific intermediate filament protein. The cell lines of PC-12 cells (rat pheochromocytoma cells), and L-2 cells (rat fibroblasts) were originally obtained from American Type Culture Collection - ATCC (Rockville MD).

2.2. Organelle specific antibodies

The preparations of the anti-MG-160 monoclonal antibody (10A8), and the immunoaffinity purified anti-MG-160 polyclonal antibodies, were described in previous publications [10,11,26]. The preparation of the monoclonal antibody 2H1, a RER marker, has been previously described [8].

2.3. Immunohistochemistry

Cells, grown on poly-α-lysine treated coverslips, were fixed with 2% paraformaldehyde for 20 min at room temperature, washed 3 times in PBS, incubated for 30 min in 0.05% saponin/10% goat serum (GS) in PBS, washed 3 times in 10% GS in PBS, incubated with primary antibody (1:1000 dilution in PBS of immunoaffinity purified rabbit anti-MG-160 antibodies, or supernatant from the anti MG-160 hybridoma 10A8) overnight at room temperature. Cultures were then washed, incubated with a biotinylated goat anti-rabbit IgG antibody, incubated with the avidin–biotin complex (ABC), and stained with dianaminobenzidine tetrahydrochloride (DAB) (5 mg DAB/10 ml Tris-saline containing 10 mM imidazole and 0.03% H2O2), according to standard methods [27,28].

2.4. Immunofluorescence

Cells, plated on poly-α-lysine treated coverslips, were rinsed with 20 mM phosphate buffer pH 7.2/0.45M NaCl (solution B), and fixed in 2% paraformaldehyde (20 min), incubated (30 min) with 20 mM phosphate buffer pH 7.2/5% saponin/0.45M NaCl/0.3% fish gelatin (solution A), rinsed with solution B, incubated with blocking solution made with 10% serum of the same species used for the secondary antibody in solution B (30 min), incubated with primary antibody in solution A, washed in solution B, and incubated with secondary antibody linked to FITC or RTTC in solution A (30 min), washed with solution B (15 min), washed in 1:10 dilution of Solution B to remove non specific binding of antibodies in high salt, and mounted in Mowiol (Polysciences, Inc.). For the detection of antigens expressed on cell surfaces, cells were incubated with antibodies before fixation (supernatants from A2B5 hybridoma and HNK-1 hybridoma, obtained from American Type Culture Collection, Rockville, MD) [1,15]. Double staining was done by incubations with primary antibodies followed by secondary FITC-conjugated antibody, followed by a second primary antibody and then an RTTC-conjugated secondary antibody. Cells were viewed with phase, rhodamine, and fluoresceine optics with a Zeiss microscope equipped with a filter system selective for RTTC and FITC excitation and observation. In each experiment, negative controls of normal preimmune serum and supernatants from a non-productive myeloma cell line (SP2/0) were used.
2.5. Electron microscopy

Cells grown on Therminox were fixed overnight at 4°C with 2.5% glutaraldehyde + 1% paraformaldehyde in 0.1% cacodylate buffer pH 7.4 + 0.002% CaCl₂. Subsequently cultures were postfixed in 1% osmium tetroxide + 1.5% potassium ferrocyanide, dehydrated in ethanol, and embedded in Araldite. Sections (8–10 nm thick) were stained with lead and uranyl salts and viewed in a transmission electron microscope (JEOL 100CX) at 80 kV [32,68].

2.6. Brefeldin A (BFA) treatment

BFA (Sigma) stock solution diluted in ethanol, was diluted in PBS and applied to cultures at a concentration of 5 μg/ml for periods of 30 min, or as specifically indicated in the text. Control experiments included incubation of cultures for the same time periods with the same dilutions of ethanol used to dissolve BFA.

3. Results

3.1. Detection of MG-160 in processes of astrocytes in vivo

To confirm and extend a previous ultrastructural immunocytochemical observation from this laboratory on the presence of GA in astrocytic processes in rat brain sections [68], we stained by the indirect immunoperoxidase method, using immuno-affinity purified rabbit polyclonal antibodies against MG-160, formalin-fixed, paraffin embedded, sections of rat brain and spinal cord. Immunostaining showed perinuclear GA staining in all cells. As expected, proximal neuronal dendritic processes contained short extensions of GA. In addition, areas of white matter (devoid of neuronal dendrites) also exhibited linear staining of occasional processes, consistent with those of astrocytes (Fig. 1).

3.2. Detection of MG-160, a Golgi specific protein, in astrocytes in culture

The monoclonal (10A8) and polyclonal antibodies against MG-160 detected the GA in rat astrocytic cell cultures in virtually 100% of cells. The stain was cytoplasmic, mostly perinuclear and in a granular or reticular (network) form, consistent with the morphology and distribution of the GA (Fig. 2).
Fig. 4. Double immunofluorescence staining of type II astrocytes with delicate branching processes. GFAP staining (A- FITC) and anti MG-160 (B- RITC) are seen in the same cell. A2B5 staining (C- FITC) and anti MG-160 (D- RITC) are seen in a second cell. HNK-1 staining (E- RITC) and anti MG-160 (F- FITC) are seen in a third cell. Only perinuclear staining without extension into cell processes is seen in these type II astrocytes.

Fig. 3. Double immunofluorescence staining of a subgroup of type I astrocyte with anti MG-160 (A- RITC) and GFAP (B- FITC). In this GFAP-positive cell with three processes, GA staining is seen only in one process (×630). The effect of BFA on the cytoskeleton of rat cultured astrocytes stained by immunofluorescence with anti GFAP antibodies before (C) and after (D) 48 h of BFA treatment (FITC ×630).
Staining of MG-160 in processes in rat astrocyte enriched cultures was detected by immunohistochemistry and immunofluorescence with both polyclonal and monoclonal antibodies against MG-160. Staining of MG-160 in processes appeared in approximately 10–20% of the cells (in cultures ranging from 95% to 98% of GFAP-positive cells). Staining of GA in processes was also granular and in some cells in continuity with the perinuclear GA (Fig. 2). To confirm that cells which expressed MG-160 in processes were astrocytes, double-labeling immunofluorescence with anti-MG-160 and astrocyte-specific intermediate filament marker (GFAP) antibodies were performed. All cells with staining of the GA in processes were GFAP positive (Fig. 3A,B).

3.3. MG-160 expression in cultures enriched of astrocytic subtypes

The morphology of cells expressing MG-160 in their processes was consistently of type I astrocytes. In mixed glial cultures these cells were flat and constituted part of the adherent lower layer. These cells contained abundant cytoplasm and a small number of wide flat processes. The staining of the GA in perikarya of type I astrocytes was more abundant and in the form of a network while in type II astrocytes the staining of the GA was punctate (Figs. 2–4). MG-160 was detected only in wide, non-branching processes of type I astrocytes and not in delicate branching processes of type II astrocytes. To further characterize the astrocytic cell type expressing MG-160, the differential adhesion (‘shake-off’) technique was used, adapted from McCarthy and de Vellis [50]. Loosely attached cells were shaken off during incubation in an orbital shaker at 37°C/250 rpm for 18 h and then plated on coverslips.

In cultures of adherent cells, enriched in type I astrocytes, 90% of cells were positive for GFAP and negative for A2B5 antigens. On average, about 20% of type I astrocytes contained extensions of the GA in processes.

Following ‘shake off’ the loosely adherent layer of mixed glial cultures was transferred to coverslips and incubated with 10% fetal bovine serum to promote development of type II astrocytes instead of oligodendrocytes which require serum-free medium [58]. These cultures were enriched for type II astrocytes and had over 90% of A2B5-positive, GFAP-positive cells. Type II enriched astrocytic cultures had only a small perinuclear GA staining with anti-MG-160 antibodies. In contrast to type I astrocytes, in type II astrocytes there was no evidence for extensions of the GA into cell processes. Only rare cells in type II enriched cultures displayed GA staining in processes, however, these cells had the distinct morphology of contaminating type I flat astrocytes.

3.4. Subtyping by double labeling of cells containing peripheral GA

Since cultures were not 100% pure for any cell type we wished to further confirm that GA in cell processes was present only in type I astrocytes. Cells were double labeled with A2B5 and anti-MG-160 in both mixed glial and type-enriched cultures. In astrocytic cultures, A2B5 is considered to be a marker that identifies type II astrocytes and their precursors [54]. Only A2B5-negative cells (type I astrocytes) exhibited MG-160 staining in processes. These cells were GFAP positive when double stained with GFAP and anti-MG-160 (Fig. 3A,B). A2B5-positive cells which were GFAP positive had only a small perinuclear GA staining with anti-MG-160 antibodies (Fig. 4A–D). To further confirm that type II astrocytes did not contain GA in processes, another astrocyte type II marker, HNK-1, was used with essentially the same results (Fig. 4E,F). HNK-1 belongs to a group of markers (L-2/HNK-1/J1/Elec-39) against surface adhesion molecules such as myelin associated glycoprotein (MAG) which are present in a subtype of astrocytes (type II) associated with axons in perinodal locations [1,21,35,63].

3.5. Polarity of the GA in type I astrocytes

In tissue sections and culture, astrocytes have processes which do not display distinct patterns of polarization. Therefore, we asked whether an analysis of the orientation of the GA may reveal possible internal polarization. In type I astrocytes with either several or only two processes (bipolar, or spindle cells), MG-160 immunoreactivity was detected only in one process per cell (Figs. 2, 3 and 5A).

We then asked whether the polarity of the GA in one process of certain type I astrocytes was also displayed by other cell organelles. The most closely functionally and structurally related organelle to the GA is the RER. In order to examine the differential presence of GA vs RER in these cells we performed double labeling by immunofluorescence, using a polyclonal antiserum against MG-160 as a marker for the GA, and a monoclonal antibody against a RER antigen 2H1. Astrocytes expressing linear staining of MG-160 in one process exhibited RER staining in the entire cytoplasm and in all other processes including the one stained for MG-160 (Fig. 5). In unstained preparations the unique cell process containing the GA could not be distinguished from other cell processes not containing the organelle.

3.6. Short-term effect of Brefeldin A on the GA of astrocytes

In many mammalian cells, Brefeldin A, a secretion blocker, disperses the cisternae of the stack of the GA,
Fig. 5. Double labeling of the same cell by immunofluorescence, using RITC combined with anti-MG-160 as a marker for the GA (A), and FITC combined with 2H1 as a marker for the RER (B). A bipolar astrocyte is depicted, expressing linear staining of MG-160 in one process (A), and RER staining in the entire cytoplasm and both processes (B).

which subsequently fuse with membranes of the RER. In BFA-treated cells, the cisternae and vesicles of the Trans Golgi Network (TGN) aggregate in the form of tubules and vesicles around the centriole. Previous studies from other laboratories showed that enzymes of cisternae of the Golgi stack are redistributed to the RER [12,47]. In contrast to the Golgi stacks, which under the exposure of cells to BFA fuse with the RER, cisternae of the TGN under BFA treatment collapse around the microtubule organizing center [31,60].

In order to investigate whether the immunostained (MG-160) elements of astrocytic processes are indeed part of the GA, we treated cultures of astrocytes with BFA. Following treatment of astrocytic cultures with increasing amounts of BFA, a change in MG-160 distribution was observed (Table 1). Instead of the usual perinuclear staining of the GA which is in the form of coarse granules or network, BFA treatment caused a fine granular staining of MG-160, dispersed through the entire cytoplasm. A plateau of effect related to the dose of BFA occurred with amounts greater than 1 µg/ml (Table 1). A complete dispersion of the MG-160 immunostaining occurred with concentrations of 1 or 5 µg/ml of BFA (Fig. 6). Since BFA was dissolved in ethanol we conducted control experiments in which cultures were incubated with the same concentrations of ethanol used to dissolve the BFA. In these experiments, MG-160 staining was not affected by the ethanol treatment.

The kinetics of GA dispersion were compared between astrocytes and other cells. Dispersion of the GA in astrocytes, PC-12 cells (rat pheochromocytoma cell line) and L2 cells (mouse transformed fibroblasts cell line) was complete 10–15 min after the beginning of treatment. Staining of the astrocytic cultures for the RER with monoclonal antibody 2H1 reacting with a 60–65 kDa polypeptide [8] revealed that the same concentrations of BFA which disrupted the GA did not affect the structure of the RER (Table 1). Both GA in astrocytic perikarya and the putative elements of the GA in processes dispersed with BFA treatment. This observation confirms that astrocytic processes indeed contain elements of the GA.

Since the effect of BFA is reversible, we examined the recovery of astrocytic and PC-12 cell cultures following BFA treatment. After a 30-min treatment with BFA, which caused complete dissociation of the GA as judged by the MG-160 stain, cells were washed and incubated with fresh medium. Reassembly of MG-160 was gradually observed and was complete within 60–120 min. The kinetics of BFA effect and recovery were similar in both astrocytes and PC-12 cells. The pattern of GA staining in astrocytes after recovery from a 30-min BFA treatment was identical to the GA staining before BFA treatment.

Since process formation in astrocytes can be a dynamic event modulated by various chemicals [19,66] we examined the effect of BFA on astrocytic processes after a longer exposure to BFA. Astrocyte cultures exposed to 5 µg/ml of BFA once and examined 24 h later, or cultures exposed to the same amount of BFA

| Dose (µg/ml) | Effect |
|-------------|--------|
| 0.01        | no effect on the GA |
| 0.1         | partial dissociation of the GA |
| 1.0         | complete dissociation of the GA |
| 5.0         | complete dissociation of the GA |
| 10.0        | no effect on the RER |

* Primary newborn rat astrocytic cultures were incubated with each of the above doses of BFA for 30 min, then fixed in 5% GAA/95% ethanol and the effect of BFA was analyzed by indirect immunoperoxidase staining using rabbit-anti-MG-160 antibodies or 2H1, a monoclonal antibody against a RER protein.
for four 2-h periods and examined at the end of the 8-h period, did not reveal any change in the number of processes, as judged by immunoperoxidase reaction against MG-160, an organelle specific marker of the GA.

3.7. Long-term effect of Brefeldin A on astrocytic MG-160

The effect of BFA on the redistribution of GA elements into the RER, although a reversible phenomenon when applied for short periods, has eventually detrimental consequences on the vitality and function of cells. When cultured L-2 cells or PC-12 cells were exposed to continuous 1 μg/ml of BFA treatment for 24 h, the majority of cells exhibited degenerative changes consisting of shrinkage and hyperchromasia of nuclei, pyknosis of cytoplasm, and kariorhexis, and cells completely disappeared by 48 h. In contrast, primary glial cell cultures survived the 1 μg/ml of BFA treatment, and numerous cells were present after 72 h in BFA. Immunoperoxidase staining for MG-160 of cultures maintained in BFA for 72 h revealed that the effect of the drug on the dispersion of the GA was still present in all surviving cells similar to the effect after 24 h (Fig. 6). To analyze the nature of surviving cells under BFA, double-labeling by immunofluorescence was performed 48 h after the initial introduction of BFA (1 μg/ml) into the medium. All cells showed the BFA effect on the GA as expressed by a diffuse granular MG-160 staining. The majority of cells were GFAP positive, although occasional GFAP negative flat cells with abundant cytoplasm (presumably macrophage/microglia cells) were also present. Occasional HNK-1 positive cells were present. Thus both type I and type II astrocytes resisted the prolonged BFA treatment.

To test whether BFA is partially metabolized and 'detoxified' in the astrocytic culture, we compared primary glial cultures treated with 5 μg/ml BFA only once and kept for 96 h, to cultures that were washed every 24 h and replenished with the same dose of fresh BFA. Cultures with one BFA treatment survived during the 96-h observation period, while cultures which were supplied with new BFA died between 72-96 h. In both cultures the GA was dispersed as shown by staining for MG-160. Control experiments using similar dilutions of ethanol and PBS (which were used to dissolve and dilute BFA) did not affect the pattern of GA staining or the concentration of cells on the cover-
slip. Thus in addition to its continuous effect on the GA, BFA or its metabolites may have other effects linked to the viability of cells in culture.

3.8. Long-term effect of Brefeldin A on the cytoskeleton of astrocytes

Cells exposed to BFA (one treatment of 5 μg/ml) for 2–4 days exhibited somewhat shorter processes. To test whether prolonged exposure to BFA affects the cytoskeleton of astrocytes, GFAP staining was performed at 24 and 48 h after an initial exposure of cultures to 5 μg/ml of BFA. All cells showed the BFA effect on the GA as expressed by a diffuse granular staining for MG-160. After 24 h, double staining with GFAP and MG-160 showed a coarser network of GFAP staining in cells with dispersed GA, and the beginning of perinuclear condensation. After 48 h in BFA, the effect was more pronounced and occasional cells exhibited collapse of GFAP to a form of a perinuclear ‘ball’ while GFAP stain was absent in the rest of the cytoplasm and processes (Fig. 3C,D). Both the GA and GFAP network were reconstituted in cultures treated with BFA for 96 h, washed, placed in fresh media and observed 24 h later.

3.9. Electron microscopy

Astrocytic cultures were examined by transmission electron microscopy. Perinuclear GA with the characteristic membrane-bounded stack of flat cisternae was detected in all cells. In addition, flat cells with broad processes, exhibited characteristic stacks of cisternae of the GA which were parallel to the long axis of the process, and were approximately perpendicular to the orientation of the GA in the perikaryon (Fig. 7). Only one process per cell showed evidence of GA elements. Thus, electron microscopy corroborated the immunohistochemical findings of polarity of the GA in type I astrocytic processes. Moreover, the ultrastructure of the GA in processes appeared identical to that in the perinuclear areas. Cells containing GA in processes were identified as astrocytes by the presence of bundles of intracytoplasmic intermediate filaments. Only broad processes of some cells (which belong to type I astrocytes) contained elements of the GA, while delicate branching processes (which belong to type II astrocytes) did not.

4. Discussion

Considerable differences exist among the GA of different cell types. For example, in contrast to liver Golgi and similar to renal Golgi, neuronal Golgi contains high PAPS cebrosod sulfotransferase [22,49]. Cell-specific distributions of enzymes (glycosyltrans-
cell migration [37]. Therefore type I astrocytes with polarized GA may belong to a subpopulation of astrocytes that are motile and capable of migration in response to injury. Taken together the above evidence strongly suggests that the polarization of the GA in certain cells is not a random and insignificant phenomenon. However, the functional significance of the polarization of the GA in astrocytes remains to be investigated. The differential expression of GA in processes in the two distinct astrocytic types further emphasizes the hypothesis that functional, anatomical, and morphological differences separate these two cells which express the same intermediate filaments (GFAP). Furthermore it provides further evidence of the heterogeneity that exists among type I astrocytes.

The experiments comparing the BFA effect among various cells reveal that dissociation and reassembly of the GA in astrocytes, as revealed by the immunostaining against MG-160, is similar to that of other cells. These experiments suggest that the GA in processes has the same rate of dissociation as the perinuclear GA. The experiments of prolonged exposures of astrocytes to BFA show unique properties of these cells. Unlike other cells in culture tested in this study, and with the possible exception of macrophages, astrocytes do not succumb to GA disruption, and continue to survive in culture despite the dispersion of their GA. This observation is consistent with studies which showed that several Golgi enzymes redistributed into the ER during BFA treatment continue their functions [12]. Cell lines resistant to BFA have been described [30,34]; however, these cell lines do not exhibit dissociation of the Golgi back into the ER. Studies of astrocytic functions are now necessary to further explore the effect of BFA on astrocytes. The observation of the resistance of astrocytes to BFA may be also useful for future studies on the mechanism of the effect of BFA on these cells, and of its specific interaction with the GA.

The cytoskeleton which is intimately connected with the GA also shows changes under BFA effect. BFA treatment for 1–3 h did not destabilize the cytoskeleton (detyrosinated microtubule network) in GH3 cells derived from rat pituitary tumors [6]; however, this may be due to the fact that the effect of BFA on GFAP is evident after 48 h, at a time most other cells do not survive this treatment. BFA has also been shown to induce disassembly of actin microfilaments in BFA-sensitive cells, but not in BFA-resistant cells [69]. Our finding that BFA at 1 μg/ml does not kill astrocytes but still affects the GA and the cytoskeleton may be useful in future studies of the interaction between GA and cytoskeleton. In that regard, it would be interesting to study whether astrocytes contain β-COP and whether under BFA this protein dissociates from the GA within seconds as in other cell types [13,14].

Traditionally astrocytes have been considered as supporting cells. Astrocytes presumably fulfill functions such as regulation of cell migration and differentiation during development, support of neurons by regulating the extracellular environment for ion and neurotransmitter exchange, lipid metabolism, maintenance of the blood brain barrier and various interactions with endothelial cells and blood vessels [72].

Astrocytes are also known to be the major cells in the CNS that respond to various pathologic conditions including trauma, ischemia, inflammation, and degeneration. More recent studies define the changes that occur in reactive astrocytes: (1) proliferation and migration [17,61], (2) hypertrophy with increased cytoplasm and GFAP content [18,46], (3) changes in surface expression of MHC class I and II, and ICAM-1 molecules [73], [67], (4) production of cytokines and growth factors including IL-1, IL-3, IL-6, TNF, IFN, complement components, MIP-1, GM-CSF in response to various stimulations [25,46,24]. Cytokines are traditionally considered the product of cells which belong to the immune system. As evidenced by the nature of the reaction of astrocytes to injury, by their secretory function, by their possible ability to present antigen to lymphocytes [23], and by phagocytosis [2], astrocytes may now be considered as a potential component of the immune system intrinsic to the CNS. The entire spectrum of astrocytic functions in immune modulation and their role in immune-mediated CNS diseases is just beginning to emerge. The majority of functions described above probably occur in type I astrocytes since they are presumed to be involved in reactions to injury in the CNS [52]. In that regard, the demonstration of extensions of the GA in processes in a subpopulation of type I astrocytes may be relevant to their enhanced and specialized functions in regions adjacent to their processes.

Acknowledgements

The authors thank Jun Chen for providing the 2H1 monoclonal antibodies. This work was supported by an NIH, Biomedical Research Support Grant (BRSG), to the University of Pennsylvania (E.L.), a Thomas B. McCabe and Jeannette E. Laws McCabe Award (E.L.) and NIH Grants NS 05572 and T 32 NS 07064 (N.K.G.). Parts of this work were presented at the Annual Meetings of the American Association of Neuropathologists, Baltimore 1991, and St. Louis 1992.

References

[1] Abo, T. and Balch, C.M., A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1), J. Immunol., 127 (1981) 1024–1029.
[2] Al-Ali, S.Y., Al-Zubair, A.G. and Dawod, B., Ultrastructural study of phagocytic activities of young astrocytes in injected neonatal rat brain following intracerebral injection of colloidal carbon, *Glia*, 1 (1989) 211–218.

[3] Bacallas, R., Antony, C., Dotti, C., Karsenti, E., Stelzer, E.H. and Simons, K., The subcellular organization of Madin-Darby canine kidney cells during the formation of a polarized epithelium, *J. Cell Biol.*, 109 (1989) 2817–2832.

[4] Barres, B.A., Glial ion channels, *Curr. Opin. Neurobiol.*, 1 (1991) 354–359.

[5] Black, J.A., Waxman, S.G., Friedman, B., Elmer, L.W. and Angelides, K.J., Sodium channels in astrocytes of rat optic nerve in situ: immuno-electron microscopic studies, *Glia*, 2 (1989) 353–369.

[6] Burgess, T.L., Skoufias, D.A. and Wilson, L., Disruption of the Golgi apparatus with Brefeldin A does not destabilize the associated detyrosinated microtubule network, *Cell Motil. Cytoskel.*, 20 (1991) 289–300.

[7] Celis, A., Madsen, P., Nielsen, H.V., Rasmussen, H.H., Thiessen, H., Lauridsen, J.B., van Deurs, B. and Celis, J.E., Human astrocyte IEF 58 and 57a are associated with the Golgi apparatus, *FEBS Lett.*, 227 (1988) 14–20.

[8] Chen, Y., Hickey, W.F., Mezitis, S.G.E., Stieber, A., Lavi, E., Gonatas, J.O. and Gonatas, N.K., Monoclonal antibody 2HI detects a 60–65 kD membrane polypeptide of the rough endoplasmic reticulum of neurons and stains selectively cells of several rat tissues, *J. Histochem. Cytochem.*, 39 (1991) 635–643.

[9] Chicheportiche, Y. and Tartakoff, A.M., Monoclonal antibodies as markers of the endocytic and secretory pathways, *Eur. J. Cell Biol.*, 44 (1987) 135–143.

[10] Croul, S.E., Mezitis, S.G.E. and Gonatas, N.K., An anti-organellar antibody in pathology. The chromatoxytic reaction studied with a monoclonal antibody against the Golgi apparatus, *Am. J. Pathol.*, 133 (1988) 355–362.

[11] Croul, S.E., Mezitis, S.G.E., Stieber, A., Chen, Y., Gonatas, J.O., Groud. B. and Gonatas, N.K., Immunohistochemical visualization of the Golgi apparatus in several species, including human, and tissue with antiserum against MG-160, a sialoglycoprotein of rat Golgi apparatus, *J. Histochem. Cytochem.*, 38 (1990) 957–963.

[12] Davey, W., Russ, G. and Yewdell, J.W., Brefeldin A redistributes resident and itinerant Golgi proteins to the endoplasmic reticulum, *J. Cell Biol.*, 109 (1989) 61–72.

[13] Duden, R., Allan, V. and Kreis, T., Involvement of β-COP in membrane traffic through the Golgi complex, *Trends in Cell Biol.*, 1 (1991) 14–19.

[14] Duden, R., Griffiths, G., Frank, R., Argos, P. and Kreis, T.E., β-COP: a 110 kD protein associated with non-clathrin-coated vesicles of the Golgi complex, shows homology to β-adaptin,*Cell*, 64 (1991) 649–665.

[15] Eisenbarth, G.S., Walsh, F.S. and Nirenberg, M., Monoclonal antibody against the Golgi apparatus, *Proc. Natl. Acad. Sci. USA*, 76 (1979) 4913–4917.

[16] Eng, L.F., Regulation of glial intermediate filaments in astrogliosis, *Proc. Natl. Acad. Sci. USA*, 76 (1979) 4913–4917.

[17] Eng, L.F., Reier, P.J. and Houle, J.D., Astrocyte activation and fibrous gliosis: glial fibrillary acidic protein immunostaining of astrocytes following intrasplancic cord grafting of fetal CNS tissue. In F.J. Seil, H. Herbert and B.M. Carlson (Eds.), *Progress in Brain Research*, Elsevier, Amsterdam, 1987, pp. 439–455.

[18] Eng, L.F. and Shiruba, R.A., Glial fibrillary acidic protein: a review of structure, function and clinical applications. In P.J. Marango, I. Campbell and R.M. Cohen (Eds.), *Neuronal and Glial Proteins: Structure, Function, and Clinical Application*, Academic Press, San Diego, 1988, pp. 339–359.

[19] Facci, L., Skaper, S.D., Levin, D.L. and Varon, S., Dissociation of the stellate morphology from intracellular cyclic AMP levels in cultured rat brain astroglial cells: effect of ganglioside GM1 and lysophosphatidylserine, *J. Neurochem.*, 48 (1987) 566–573.

[20] Farquhar, M.G. and Palade, G.E., The Golgi apparatus (complex)–(1954–1981) from artifact to center stage. *J. Cell. Biol.*, 91 (1981) 775–1035.

[21] ffrench-Constant, C. and Raff, M.C., The oligodendrocyte-type-2 astrocyte cell lineage is specialized for myelination, *Nature*, 323 (1986) 335–338.

[22] Fleischer, B. and Zambro, F., Golgi apparatus of rat kidney. Preparation and role in sulphate formation, *J. Biol. Chem.*, 249 (1974) 5995.

[23] Fontana, A., Fieritz, W. and Weckerle, H., Astrocytes present myelin basic protein to encephalitogenic T cells, *Nature*, 307 (1984) 273–276.

[24] Fontana, A., Frei, K., Bodmer, S. and Hofer, E., Immune mediated encephalitis: on the role of antigen presenting cells in the brain, *Immunol. Rev.*, 100 (1987) 185–201.

[25] Fontana, A., Kristensen, F., Dubs, R., Gemsa, D. and Weber, E., Production of prostaglandin E and interleukin like factors by cultured astrocytes and C-6 glioma cells, *Immunol., 129 (1982) 2419.

[26] Fontana, A., Kristensen, F., Dubs, R., Gemsa, D. and Weber, E., Production of prostaglandin E and interleukin like factors by cultured astrocytes and C-6 glioma cells, *Immunol., 129 (1982) 2419.

[27] Graham, C.R. and Karnovsky, M.J., The early stages of absorption of injected horseradish peroxidase in the proximal tubules of mouse kidney: ultrastructural cytochemistry by a new technique, *J. Histochem. Cytochem.*, 14 (1966) 291–302.

[28] Guesdon, J.-L., Ternynck, T. and Avrameas, S., The use of avidin–biotin interaction in immunoenzymatic techniques, *J. Histochem. Cytochem.*, 27 (1979) 1131–1139.

[29] Hosli, E. and Hosli, L., Receptors for neurotransmitters on astrocytes in the mammalian central nervous system, *Proc. Neurorobiol., 40 (1993) 477–506.

[30] Hunziker, W., Whitney, J.A. and Mellman, I., Selective inhibition of transcytosis by Brefeldin A in MDCK cells, *Cell*, 67 (1991) 617–627.

[31] Johnston, A.P., Stieber, A. and Gonatas, N.K., Retrograde traffic of MG-160, a medial sialoglycoprotein, from the Trans Golgi Network to the Golgi cisternae, in press.

[32] Karnovsky, M.J., Use of ferrocyanide-reduced osmium tetroxide in electron microscopy, *Eleventh Annual Meeting of the American Society for Cell Biology*, Abstract 284 (1971) 146.

[33] Kerr, J.B., An ultrastructural and morphometric analysis of the Sertoli cell during the spermatogenic cycle of the rat, *Anat. Embryol.*, 179 (1988) 191–203.

[34] Kissakis, N.T., Roth, M.G. and Bloom, G.S., PK1 cells contain a nondiffusible, dominant factor that makes the Golgi apparatus resistant to Brefeldin A, *J. Cell Biol.*, 113 (1991) 1009–1023.

[35] Kuchler, S., Zanetta, J.-P., Bon, S., Zaepfel, M., Massoulié, J. and Vincendon, G., Expression and localization in the developing cerebellum of the carbohydrate epitopes revealed by Eloc-39, an IgM monoclonal antibody related to HNK-1, *Neuroscience*, 41 (1991) 551–562.

[36] Kupfer, A., Dennert, G. and Singer, S.J., Polarization of the Golgi apparatus and the microtubule-organizing center within cloned natural killer cells bound to their targets, *Proc. Natl. Acad. Sci. USA*, 80 (1983) 7224–7228.

[37] Kupfer, A., Kronesbusch, P.J., Rose, J.K. and Singer, S.J., A critical role for the polarization of membrane recycling in cell motility, *Cell Motil. Cytoskel.*, 8 (1987) 182–189.

[38] Kupfer, A., Louvard, D. and Singer, S.J., The polarization of the Golgi apparatus and the microtubule-organizing center in cul-
tured fibroblasts at the edge of an experimental wound, Proc. Natl. Acad. Sci. USA, 79 (1982) 2603–2607.

Kupfer, A., Singer, S.J. and Dennert, G., On the mechanism of unidirectional killing in mixtures of two cytotoxic T lymphocytes. Unidirectional polarization of cytoplasmic organelles and the membrane associated cytoskeleton in the effector cell, J. Exp. Med., 163 (1986) 489–498.

Lacocq, J. and Montesano, R., Non random positioning of Golgi apparatus in pancreatic B cells, Anat. Rec., 213 (1985) 182–186.

Lavi, E., Suzumura, A., Murray, E.M., Silberberg, D.H., and Weiss, S.R., Induction of MHC class I antigens on glial cells is dependent on persistent mouse hepatitis virus infection, J. Neuroimmunol., 22 (1989) 107–111.

Lee, V.M.-Y., Page, C.D., Wu, H.L. and Schlaepfer, W.W., Monoclonal antibodies to gel excised glial filament protein and their reactivities with other intermediate filament proteins, J. Neurochem., 42 (1984) 25.

Levi, G., Gallo, V. and Ciotti, M.T., Bipotential precursors of putative fibrous astrocytes and oligodendrocytes in rat cerebellar cultures express distinct surface features and 'neuron-like' gamma-aminobutyric acid transport, Proc. Natl. Acad. Sci. USA, 83 (1986) 1504–1508.

Levison, S.W. and Goldman, J.E., Astrocyte origins. In S. Murphey (Ed.), Astrocytes: Pharmacology and Function, Academic Press, San Diego, CA, 1993, pp. 1–22.

Lieberman, A.P., Pitha, P.M., Shin, H.S. and Shin, M.L., Production of tumor necrosis factor and other cytokines by astrocytes treated with Brefeldin A: evidence for membrane cycling from Golgi to ER, Cell, 56 (1989) 801–813.

Louvard, D., Reggio, H. and Warren, G., Antibodies to the Golgi complex and the rough endoplasmic reticulum, J. Cell Biol., 92 (1982) 92–107.

Mackhann, G.M. and Ho, W., The in vivo and in vitro synthesis of sulphatides during development, J. Neurochem., 14 (1967) 717–724.

McCarthy, K.D. and de Vellis, J., Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue, J. Cell Biol., 85 (1980) 890–902.

McCarthy, K.D. and Salm, A.K., Pharmacologically-distinct subsets of astroglia can be identified by their calcium response to neurotransmitters, Neuroscience, 41 (1991) 325–333.

Miller, R.H., Abney, E.R., frenchen-Constant, C., Lindsay, R., Patel, R., Stone, J. and Raff, M.C., Is reactive giosis a property of a distinct subpopulation of astrocytes?, J. Neurosci., 6 (1986) 22–29.

Miller, R.H., frenchen-Constant, C. and Raff, M.C., The macroglial cells of the rat optic nerve, Annu. Rev. Neurosci., 12 (1989) 517.

Miller, R.H. and Raff, M.C., Fibrous and protoplasmic astrocytes are biochemically and developmentally distinct, J. Neurosci., 4 (1984) 585–592.

Mourelatos, Z., Adler, H., Hirano, A., Donnenfeld, H., Gonatas, J.O. and Gonatas, N.K., Fragmentation of the Golgi apparatus of motor neurons in amyotrophic lateral sclerosis revealed by organelle-specific antibodies, Proc. Natl. Acad. Sci. USA, 87 (1990) 4393–4395.

Newman, E.A., Inward-rectifying potassium channels in retinal glial (Muller) cells, J. Neurosci., 13 (1993) 3333–3345.

Palade, G.E., Intracellular aspects of the process of protein transport, Science, 189 (1975) 347–358.

Raff, M.C., Glial cell diversification in the rat optic nerve, Science, 243 (1989) 1450–1455.

Raff, M.C., Miller, R.H. and Noble, M., A glial progenitor cell that develops in vitro into an astrocyte depending on culture medium, Nature, 303 (1983) 390–396.

Reaves, B. and Banting, G., Perturbation of the morphology of the trans Golgi network following Brefeldin A treatment: redistribution of a TGN-specific integral membrane protein, TGN38, J. Cell Biol., 116 (1992) 85–94.

Reier, P.J., Eng, L.F. and Jakeman, L., Reactive astrocyte and axonal overgrowth in the injured CNS: is glosis really an impediment to regeneration? In J.I. Selig (Ed.), Neuroregeneration Research for the Clinician, Seat Fed., Alan R. Liss Inc., New York, 1989, pp. 183–209.

Roth, J., Taatjes, D.J., Weinstein, J., Paulson, J.C., Greenwell, P. and Watkins, W.M., Differential subcompartmentation of terminal glycosylation in the Golgi apparatus of intestinal absorptive and goblet cells, J. Biol. Chem., 261 (1986) 14307–14312.

Sadou, R., Fahrig, T. and Schachner, M., Binding properties of liposomes containing the myelin-associated glycoprotein MAG to neural cell cultures, J. Neurosci. Res., 25 (1990) 1–13.

Saraste, J., Bale, G.E. and Farquhar, M.G., Antibodies to rat pancreas Golgi subfractions: identification of a 58-kD cis-Golgi protein, J. Cell. Biol., 105 (1987) 2021–2029.

Schweitzer, A., Fransen, J.A.M., Bachi, T., Ginsel, L., and Hauri, H.P., Identification of a monoclonal antibody of a 53-kD protein associated with the tubulo-vesicular compartment at the cis side of the Golgi apparatus, J. Cell. Biol., 107 (1989) 1643–1653.

Skaper, S.D., Facci, L., Rudge, J., Kato, K., Manthorpe, M. and Varon, S., Morphological modulation of cultured rat brain astroglial cells: antagonism by Ganglioside GM1, J. Neurochem., 25 (1986) 21–31.

Sobel, R.A., Mitchell, M.E. and Fondon, G., Intercellular adhesion molecule 1 (ICAM-1) in cellular immune reactions in the central nervous system, Am. J. Pathol., 136 (1990) 1309–1316.

Stieber, A., Gona Ïas, J.O., Gona Ïas, N.K. and Louvard, D., The Golgi apparatus complex of neurons and astrocytes studied with an anti-organelle antibody. Brain Res., 408 (1987) 13–21.

Sugai, M., Chen, C.-H. and Wu, H.C., Staphylococcal ADP-ribosyltransferase-sensitive small G protein is involved in brefeldin A action, J. Biol. Chem., 267 (1992) 21297–21299.

Suzumura, A., Lavi, E., Bhat, S., Murasko, D.M., Weiss, S.R. and Silberberg, D.H., Induction of glial cell MHC antigen expression in neurotropic coronavirus infection: characterization of the H-2 inducing soluble factor elaborated by infected brain cells, J. Immunol., (1988) 2068–2072.

Suzumura, A., Lavi, E., Weiss, S.R. and Silberberg, D.H., Coronavirus infection induces H-2 antigen expression on oligodendrocytes and astrocytes, Science, 232 (1986) 991–993.

Taylor, D.B., Development of knowledge about astrocytes since Virchow, In M.D. Norenberg, L. Hertz and A. Schousboe (Eds.), The Biochemical Pathology of Astrocytes, Alan R. Liss, New York, 1988, pp. 3–18.

Traugott, U., Multiple sclerosis: relevance of class I and class II MHC expressing cells to lesion development, J. Neuroimmunol., 16 (1987) 283–302.

Wilkin, G.P., Marrriott, D.R. and Cholewinski, A.J., Astrocyte heterogeneity, Trends Neurosci., 13 (1990) 43–46.

Yuan, L., Barrassal, G., Bonifacino, J. and Sandoval, I.V., Two integral membrane proteins located in the cis-medial ant-trans part of the Golgi system acquire signalated N-linked carbohydrates and display different turnovers and sensitivity to cAMP dependent phosphorylation, J. Cell. Biol., 105 (1987) 215–227.